JIN MEDICAL INTERNATIONAL-A
ZJYLNASDAQ🏆 #4239 by market capUS Equity
$2.92▼ $0.03 (−1.02%)
Live1h—
24h▼ 1.0%
7d▲ 32.1%
14d▲ 43.1%
30d▲ 56.1%
1y▼ 77.1%
🏦Market Cap
$23M
Small Cap
📈Revenue Growth (YoY)
-12.0%
Declining
📊Gross Margin
29.2%
Moderate
💵FCF Margin
2.5%
Thin
⚖️P/S Ratio
1.2x
Cheap
Otter Score
57
Weak
Trading Snapshot
- Day Range
- $2.88 – $2.98
- 52-Week Range
- $1.53 – $17.18
- Volume
- $3.30B
- Avg Volume
- $2.87B
- Shares Outstanding
- 7.8M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $12M
- Last Q Revenue
- $3M
- P/E Ratio
- 21.6
- P/S Ratio
- 1.2x
- EPS (TTM)
- $0.15
- Dividend Yield
- —
Why Investors Own ZJYL
- ✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$12M▲ +44.0% YoY
Gross Margin (TTM)
66.8%▲ +4.1% YoY
Operating Income (TTM)
$3M▲ +44.0% YoY
Free Cash Flow (TTM)
$3M▲ +44.0% YoY
About JIN MEDICAL INTERNATIONAL-A
A company profile for JIN MEDICAL INTERNATIONAL-A isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
57/100
Analyst Price Target
ⓘAverage Target
$3.11
▲ +6.7% Upside
High Target$3.52
Low Target$2.66
Based on 25 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
JIN MEDICAL INTERNATIONAL-A tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift ZJYL price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
JIN MEDICAL INTERNATIONAL-A announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.